Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection
Cancers · 18.11.2026 · 18 (22) · 3695
DOI: 10.3390/cancers18223695 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 18.11.2026. Verfasst von Vasilios Lygizos und 10 weiteren Autor:innen. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Contraceptive counseling in gynecologic oncology requires integration of medical eligibility, contraceptive pharmacology, tumor characteristics, and treatment status. This narrative review synthesizes professional guidance and selected clinical, epidemiologic, and mechanistic literature, distinguishing direct post-diagnosis contraceptive outcomes from indirect evidence. General-population studies associate combined oral contraception with increased venous thromboembolism (VTE), with differences between formulations; most progestin-only pills, implants, and levonorgestrel intrauterine systems show no consistent increase, whereas depot medroxyprogesterone acetate has a VTE signal. These estimates do not quantify formulation-specific risk in patients with gynecologic cancer. Histotype and endocrine treatment warrant particular attention in low-grade serous and endometrioid ovarian carcinomas, adult granulosa cell tumors, and low-grade endometrial stromal sarcoma. Molecular prognostic markers have not been validated as predictors of contraceptive effects on recurrence or survival. A qualitative framework, an annotated method-selection table, and a decision pathway organize formulation, host, tumor, treatment, and procedural considerations, including perimenopausal use and regional prescribing differences. The framework is an author-derived synthesis rather than a validated prediction model, evidence-grading system, or medical eligibility classification. It is intended to support individualized, multidisciplinary counseling alongside established recommendations. Prospective studies of post-diagnosis exposure, recurrence, survival, and vascular outcomes are needed before its clinical utility can be established.
Zitieren
APA
Lygizos, V., Christodoulaki, C., Panagopoulou, R., Vlachos, D. E., Thomakos, N., Baroutis, D., Varthaliti, A., Bountouraki, G., Daskalakis, G., Panagopoulos, P., & Pergialiotis, V. (2026). Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection. Cancers, 18(22), 3695. https://doi.org/10.3390/cancers18223695
Vancouver
Lygizos V, Christodoulaki C, Panagopoulou R, Vlachos DE, Thomakos N, Baroutis D, et al. Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection. Cancers. 2026;18(22):3695. doi:10.3390/cancers18223695
BibTeX
@article{Lygizos2026,
author = {Lygizos, Vasilios and Christodoulaki, Chrysi and Panagopoulou, Rafaela and Vlachos, Dimitrios Efthymios and Thomakos, Nikolaos and Baroutis, Dimitris and Varthaliti, Antonia and Bountouraki, Georgia and Daskalakis, George and Panagopoulos, Periklis and Pergialiotis, Vasilios},
title = {Contraception in Gynecologic Oncology: Pharmacologic Determinants, Thromboembolic Risk, and Tumor-Specific Clinical Selection},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3695},
doi = {10.3390/cancers18223695}
}
EUVIMED